What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Internal medicine
Cancer research, Internal medicine, Multiple myeloma, In vivo and Cell growth are his primary areas of study.
Pierfrancesco Tassone combines subjects such as Cancer cell, Cell culture, Apoptosis and Bortezomib with his study of Cancer research.
Downregulation and upregulation and Gene silencing is closely connected to PTEN in his research, which is encompassed under the umbrella topic of Multiple myeloma.
His In vivo research includes elements of Immunology and Transfection.
In his study, which falls under the umbrella issue of Cell growth, MAPK/ERK pathway is strongly linked to Protein kinase B.
His research integrates issues of microRNA and Oncology in his study of Cancer.
His most cited work include:
- Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma (319 citations)
- Mir-34: A New Weapon Against Cancer? (311 citations)
- Mir-34: A New Weapon Against Cancer? (311 citations)
What are the main themes of his work throughout his whole career to date?
Pierfrancesco Tassone focuses on Cancer research, Multiple myeloma, Internal medicine, Molecular biology and Cell growth.
His studies in Cancer research integrate themes in fields like Apoptosis, microRNA, Bone marrow and In vivo.
His Multiple myeloma research focuses on Bone disease and how it relates to Bone resorption.
Pierfrancesco Tassone works mostly in the field of Internal medicine, limiting it down to topics relating to Oncology and, in certain cases, Bevacizumab, Clinical trial and Randomized controlled trial, as a part of the same area of interest.
Pierfrancesco Tassone has included themes like Cell culture, Transfection, Monoclonal antibody and Antigen in his Molecular biology study.
His Cell growth study combines topics from a wide range of disciplines, such as Cell, Cell cycle, Cytokine, Downregulation and upregulation and Signal transduction.
He most often published in these fields:
- Cancer research (51.69%)
- Multiple myeloma (29.32%)
- Internal medicine (25.11%)
What were the highlights of his more recent work (between 2016-2021)?
- Cancer research (51.69%)
- Multiple myeloma (29.32%)
- Internal medicine (25.11%)
In recent papers he was focusing on the following fields of study:
Pierfrancesco Tassone mainly focuses on Cancer research, Multiple myeloma, Internal medicine, microRNA and Oncology.
His Cancer research research is multidisciplinary, relying on both DNA damage, Cell growth, Apoptosis, DNA repair and Bone marrow.
His Cell growth research is multidisciplinary, incorporating elements of NFKB1, Regulation of gene expression, Signal transduction and Tumor microenvironment.
The Multiple myeloma study combines topics in areas such as In vitro, Bone disease, Pathogenesis and Gene expression profiling.
The concepts of his microRNA study are interwoven with issues in Cell culture, Cell, Transcriptional regulation, Computational biology and In vivo.
His study in the fields of Lung cancer under the domain of Oncology overlaps with other disciplines such as Hazard ratio.
Between 2016 and 2021, his most popular works were:
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial (228 citations)
- MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches. (108 citations)
- Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. (92 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
His primary scientific interests are in Cancer research, microRNA, Multiple myeloma, Internal medicine and Cell growth.
His biological study spans a wide range of topics, including Cell, DNA damage, Apoptosis, DNA repair and Gene silencing.
The microRNA study which covers Downregulation and upregulation that intersects with EZH2, Molecular medicine, Hematology and Small interfering RNA.
His Multiple myeloma research includes themes of Immune compromised, Computational biology, Human bone and In vivo.
In his work, Chemotherapy and Liquid biopsy is strongly intertwined with Oncology, which is a subfield of Internal medicine.
His Cell growth research integrates issues from Gene knockdown, NFKB1, Signal transduction, Regulation of gene expression and Bone marrow.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
